MCNPC: early docetaxel boosts quality-adjusted survival in high-volume disease

L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano Registrati per accedere ai contenuti

Takeaway

  • Significant quality-adjusted survival benefits were seen with early docetaxel in patients with metastatic castrate-naive prostate cancer (MCNPC), particularly those with high-volume disease.

Why this matters

  • Treatment-related toxicity can negatively affect survival benefit...